Live tape
Top 8, mentions 7d6,922META1,781 mentions▲ +0.06GOOGL1,419 mentions▲ +0.03NVDA881 mentions▲ +0.09TSLA654 mentions▲ +0.06MSFT574 mentions▲ +0.06SPY567 mentions▲ +0.03AMZN550 mentions▲ +0.04AAPL496 mentions▲ +0.07

Equity · Healthcare

BIO

NYSE

Bio-Rad Laboratories, Inc.

$379.48 +0.39% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 29, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$400 $250 2 Jul 29 Sep

The line runs $297 on 2 July through $379.48 on 29 September, on a scale from $250 to $400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of BIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $297 on 2 July 2026 through $379.48 on 29 September 2026.

Market cap $10.2B
P/E (TTM) 46.3
52-week range $242 – $390.31
Avg volume 19.2K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 29, 2026

Filings 5 sets

BIO reported financials

SEC EDGAR XBRL

BIO reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.

Figure Reported Period
Revenue $2.6B 31 Dec 2025 fiscal year
Net income $759.9M 31 Dec 2025 fiscal year
Diluted EPS $27.85 31 Dec 2025 fiscal year
Total assets $10.3B 30 Jun 2026 at period end
Total equity $7.2B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

BIO earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $13.85 $651M
31 Mar 2026 Q1 2026 $-19.55 $592M
31 Dec 2025 FY 2025 $27.85 $2.58B
30 Sep 2025 Q3 2025 $-12.70 $653M
30 Jun 2025 Q2 2025 $11.67 $652M
31 Mar 2025 Q1 2025 $2.29 $585M
31 Dec 2024 FY 2025 $-25.57 $2.57B
30 Sep 2024 Q3 2024 $23.34 $650M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

BIO institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a BIO position for the quarter ended 30 Jun 2026 — a combined $155.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Added +103.8% shares 192,711 $56.0M
Fisher Asset Management Held (±25%) −1.5% shares 116,909 $34.3M
Citadel Advisors Trimmed −59.1% shares 60,819 $17.9M
Millennium Management Added +1,718.3% shares 59,895 $17.6M
GAMCO Investors Held (±25%) 26,750 $7.9M
Tudor Investment Corp Added +384.4% shares 25,000 $7.3M
D. E. Shaw & Co. Added +136.4% shares 19,256 $5.7M
Marshall Wace Trimmed −42.9% shares 18,980 $5.6M
Two Sigma Investments Held (±25%) −6.1% shares 10,320 $3.0M
Man Group Trimmed −97.9% shares 1,437 $422K

Source: SEC EDGAR 13F filings

BIO fails-to-deliver

SEC CNS data

On 14 Sep 2026, 400 shares of BIO failed to deliver (about $148K).

Settlement date Shares failed Notional % of shares out
14 Sep 2026 400 $148K 0.001%
10 Sep 2026 2,061 $777K 0.008%
08 Sep 2026 3 $1K <0.001%
03 Sep 2026 4,193 $1.6M 0.016%
25 Aug 2026 17,170 $6.6M 0.064%
18 Aug 2026 13,658 $4.9M 0.051%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in BIO

STOCK Act disclosures

The most recent congressional trade disclosed in BIO is a sale by Lois Frankel (house, FL), dated 08 Sep 2023.

Date Member Type Amount
08 Sep 2023 filed 10 Oct 2023 Lois Frankel house · Democrat–FL Sale $1K–$15K
29 Jun 2023 filed 28 Jul 2023 Lois Frankel house · Democrat–FL Purchase $1K–$15K
28 Jun 2023 filed 28 Jul 2023 Lois Frankel house · Democrat–FL Purchase $1K–$15K
30 Nov 2022 filed 29 Dec 2022 Susie Lee house · Democrat–NV Sale $1K–$15K
05 Jan 2021 filed 10 Feb 2021 Susie Lee house · Democrat–NV Sale $1K–$15K
02 Oct 2020 filed 08 Dec 2020 Susie Lee house · Democrat–NV Sale $1K–$15K
27 May 2020 filed 15 Jun 2020 Susie Lee house · Democrat–NV Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures